Form 13-F position report

NEOGENOMICS INC

Reported by EMERALD ADVISERS LLC

Company profile Manager portfolio Source filing
NEO CUSIP 64049M209 Manager CIK 0001015083
Latest reported change

Reported 1,656,219 shares, down 13,105 (0.8%) from the prior quarter.

Reported value -8.4%; share count -0.8% vs. the prior quarter.

Reduced
% of reported 13F value 1.16% This manager · Q2 2023
Shares 1,656,219 Quarter-end amount reported
Reported value $26,615,439 Fair value at quarter end
Consecutive quarters held 29 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q2 2025 Reduced 0 -855,688 (-100.0%) 0 $0 2025-08-04
Q1 2025 Reduced 855,688 -701,749 (-45.1%) 0.37% $8,120,479 2025-05-01
Q4 2024 Reduced 1,557,437 -124,777 (-7.4%) 0.99% $25,666,562 2025-02-11
Q3 2024 Reduced 1,682,214 -162,401 (-8.8%) 0.96% $24,812,657 2024-10-29
Q2 2024 Reduced 1,844,615 -61,289 (-3.2%) 1.07% $25,584,810 2024-08-06
Q1 2024 Added 1,905,904 +8,090 (0.4%) 1.21% $29,960,811 2024-05-08
Q4 2023 Reduced 1,897,814 -29,260 (-1.5%) 1.31% $30,706,635 2024-02-05
Q3 2023 Added 1,927,074 +270,855 (16.4%) 1.15% $23,703,005 2023-10-26
Q2 2023 Reduced 1,656,219 -13,105 (-0.8%) 1.16% $26,615,439 2023-07-25
Q1 2023 Reduced 1,669,324 -432,243 (-20.6%) 1.39% $29,062,931 2023-05-04
Q4 2022 Reduced 2,101,567 -38,012 (-1.8%) 0.94% $19,418,479 2023-02-03
Q3 2022 Added 2,139,579 +926,226 (76.3%) 0.95% $18,422,000 2022-10-25
Q2 2022 Added 1,213,353 +122,241 (11.2%) 0.51% $9,889,000 2022-07-29
Q1 2022 Added 1,091,112 +205,676 (23.2%) 0.51% $13,257,000 2022-04-29
Q4 2021 Reduced 885,436 -18,862 (-2.1%) 1.11% $30,211,000 2022-02-02
Q3 2021 Added 904,298 +32,276 (3.7%) 1.58% $43,623,000 2021-10-28
Five years are shown. A free account unlocks the complete reported history. Unlock full history
Institutional context

Who else reported the position

297 managers reported NEOGENOMICS INC for Q2 2023.

Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Reduced 20,776,212 -532,168 < 0.01% $333,873,726 33 qtrs
VANGUARD GROUP INC Added 14,640,814 +770,257 < 0.01% $235,277,880 41 qtrs
JANUS HENDERSON GROUP PLC Added 7,589,487 +165,135 0.08% $121,960,667 25 qtrs
BROWN ADVISORY INC Added 6,594,485 +3,281 0.17% $105,973,380 20 qtrs
T Rowe Price Investment Management Inc Added 5,059,586 +158,146 0.06% $81,308,000 4 qtrs
STATE STREET CORPORATION Added 4,926,392 +40,222 < 0.01% $79,167,119 41 qtrs
Greenhouse Funds LLLP Added 3,294,817 +364,803 4.13% $52,947,709 6 qtrs
DIMENSIONAL FUND ADVISORS LP Added 2,980,374 +287,767 0.02% $47,894,554 27 qtrs
First Light Asset Management LLC Reduced 2,692,057 -6,901 3.39% $43,261,356 39 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 2,617,439 +99,568 < 0.01% $42,062,255 41 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
July 25, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
1,205,761
Shared
0
None
450,458

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.